Introduction
============

Lymphoepithelioma carcinoma is a common type of poorly-differentiated epithelial cells in the nasopharynx \[[@B1][@B2][@B3]\]. Histologically, it appears as nests of poorly-differentiated malignant cells with syncytial growth patterns. It is associated with noticeable lymphocytic stromal infiltration. Studies on lymphoepithelioma carcinoma in the nasopharynx have found that the condition is more prevalent in Asian populations, and that it is related to Epstein-Barr virus (EBV) infection and favorable clinical outcomes \[[@B1][@B4]\]. Neoplasia with characteristics that are similar to those of nasopharyngeal lymphoepithelioma carcinoma occurring at anatomic sites other than the nasopharynx, such as the salivary glands, lungs, thymus, stomach, and uterine cervix, are referred to as lymphoepithelioma-like carcinoma (LELC) \[[@B3]\]. LELC of the uterine cervix is very rare; it accounts for only 0.63% of all cases of primary uterine cervical carcinoma in the Western world and about 5.5% of those in Japan \[[@B1][@B5]\]. A literature search about cervical LELC in PubMed uncovered only 3 English language original articles \[[@B1][@B3][@B5]\] and 9 English language case reports on 16 patients \[[@B2][@B4][@B6][@B7][@B8][@B9][@B10][@B11][@B12]\]. So far, only 3 case reports in Korean journals of obstetrics and gynecology have been published \[[@B13][@B14][@B15]\]. In the World Health Organization histological classification of tumors of the uterine cervix, LELC is classified as a subtype of squamous cell carcinoma \[[@B4]\]. Though LELC is histologically poorly differentiated, its clinical prognosis is better than that of other squamous cell carcinomas of the uterine cervix. For this reason, being able to identify the differences between LELC and other poorly-differentiated squamous cell carcinomas, lymphomas, and other lymphoproliferative disorders of the cervix is very important for correct diagnosis and treatment \[[@B2]\]. Some studies have found that EBV is associated with the pathogenesis of cervical LELC, especially in Asian woman \[[@B3]\]. However, this issue remains controversial. We herein present a case of LELC of the cervix in a 45-year-old Korean woman along with a literature review.

Case report
===========

A 45-year-old, premenopausal, Korean woman, gravida 4, parity 2, was referred to the department of obstetrics and gynecology of Pusan National University Yangsan Hospital. She visited another hospital because of vaginal bleeding that had persisted for one month. A cervical liquid-based cytology test was performed, which revealed atypical endometrial cells not otherwise specified. Endometrial sampling was recommended. On hysteroscopy, an endocervical mass was identified. A biopsy taken from the endocervical mass revealed poorly differentiated squamous cell carcinoma. The patient visited our hospital for further assessment and treatment of cervical cancer. The results of a colposcopy were unsatisfactory due to no visible transformation zone. On bimanual examination, the parametrium was soft without a palpable mass. Her past medical history was unremarkable. Her hematological profile revealed a hemoglobin level of 8.4 g/dL with normal leukocyte and platelet counts. The serum level of squamous cell carcinoma antigen (0.9 ng/mL) was within normal limits. A human papilloma virus (HPV) DNA chip test following cytobrushing of the cervix did not detect high risk HPV DNA. Magnetic resonance imaging ([Fig. 1A](#F1){ref-type="fig"}) and positron emission tomography with 2-deoxy-2-\[fluorine-18\] fluoro-D-glucose integrated with computed tomography revealed a 3.1-cm mass at the anterior aspect of the endocervix and multiple uterine myomas, all of which were less than 9 cm. No distant metastatic lesions or enlarged lymph nodes were observed. The patient was clinically diagnosed as International Federation of Gynecology and Obstetrics (FIGO) stage IB1, with no infiltration of the vaginal wall or parametrium. A radical hysterectomy and bilateral pelvic lymph node dissection, and transposition of both ovaries were performed to treat cervical cancer. Grossly, pathologic lesion was invisible in exocervix. The uterine cervix was opened at 12 o\'clock ([Fig. 1B](#F1){ref-type="fig"}). On gross section, the endocervix contained a relatively well-defined brownish-white depressed mass at 12 to 6 o\'clock, which measured 2.4×0.9 cm in size. It was 4.2 cm away from the closest vaginal cuff margin. It invaded to a depth of about 0.9 cm in the 1.5-cm-thick cervical wall. Given the macroscopic findings, the relatively well-defined endocervical mass appeared.

On microscopic examination, poorly-differentiated epithelioid cells were evident, which were made up of clusters surrounded by markedly infiltrated lymphoid cells. Because this is the typical pattern of LELC, the condition could be recognized easily even at low magnification. The cancer cells showed large, ill-defined cytoplasmic borders, abundant cytoplasm, prominent nucleoli, and syncytial growth patterns ([Fig. 1C](#F1){ref-type="fig"}). Lymphovascular invasion, perineural invasion, and lymph node metastasis were not present. *in situ* hybridization for EBV-encoded early RNAs was done in formalin-fixed paraffin-embedded tissue. The result was negative ([Fig. 1D](#F1){ref-type="fig"}). And the result of HPV polymerase chain reaction in paraffin-embedded tissue was negative. The postoperative course was uneventful, and the patient left the hospital 7 days after surgery. The final pathologic results revealed LELC of cervix. The patient has been followed up for eight months without adjuvant treatment, with an abdominal computed tomography scan taken after 6 months from surgery in an outpatient clinic, which revealed no evidence of recurrence or metastasis.

Discussion
==========

LELC of the uterine cervix is a rare variant of poorly-differentiated squamous cell carcinoma. The review of previously published cases and original articles of LELC are listed in [Table 1](#T1){ref-type="table"} \[[@B1][@B2][@B3][@B4][@B5][@B6][@B7][@B8][@B9][@B10][@B11][@B12][@B13][@B14][@B15]\]. It is made up of sheets showing a syncytial growth pattern with marked infiltration of lymphocytes in the stroma \[[@B2][@B3][@B5]\]. The incidence of cervical LELC in Asians is higher than in the Western population, just as the incidence of nasopharyngeal lymphoepithelioma carcinoma is higher in the Asian than in the Western population.

Generally, cervical LELC occurs at a younger age than do other types of cervical carcinoma. In 1977, Hasumi et al. \[[@B5]\] reported that 16 of 39 cervical LELC patients with a mean age of 43.5 years were less than 40 years old. In cases of other cervical carcinomas, only 28.2% (mean age, 48.6 years) of patients were less than 40 years old. Our patient was 45 years old, premenopausal woman, which is close to the mean age of cervical LELC patients but she was younger than LELC patients who were reported in Korean cases.

Although the morphological features of cervical LELC appear aggressive, the prognosis is better than that for other type of squamous cell carcinomas of the uterine cervix. In comparison with other carcinomas of the same FIGO stage, cervical LELC is characterized by less regional lymph node metastasis \[[@B5]\]. Tseng et al. \[[@B3]\] reported that, even in other organs, LELC tumors are associated with good clinical outcomes. The hypothesis for the good prognosis is that tumors may induce both humoral and cell-mediated immunologic reactions \[[@B5]\]. Some reports have suggested that the good prognosis may be related to the immunologic reaction caused by tumor-associated antigens, which are the host\'s response to lymphocytic infiltration. The infiltrated lymphocytes found in the stroma reflect the humoral and cell-mediated immune response to tumors. The response seems to reduce lymph node metastasis and increase the overall survival rate \[[@B1][@B5]\]. In our case, there were no lymphovascular, perineural, parametrial, or vaginal invasions, and no lymph node metastasis. The patient exhibited characteristics typical of cervical LELC.

Saroha et al. \[[@B4]\] reported that when a cervical LELC specimen is obtained from a highly inflammatory lesion or obscure tumor cells, an exact diagnosis is very difficult. For differential diagnosis of vague biopsy lesions, immunohistochemical staining for cytokeratin or epithelial membrane antigen is necessary. Tseng et al. \[[@B3]\] reported that 4 of 15 cervical LELC patients showed poorly-differentiated carcinoma on cervical biopsies taken by colposcopy, whereas the other 11 patients with cervical LELC were diagnosed histologically after radical hysterectomy. A diagnosis of cervical LELC with only a biopsy specimen is difficult. Therefore, an assessment of a hysterectomy specimen is needed for accurate diagnosis. Moreover, LELC of the uterine cervix is an important differential diagnosis, and should not be confused with other types of poorly-differentiated squamous cell carcinomas and prominent lymphoid-related neoplasia in the stroma, such as glassy cell carcinoma, which have poor prognoses \[[@B4][@B5]\]. In our case, an initial cervical biopsy from endocervical mass showed poorly-differentiated squamous cell carcinoma. The diagnosis was confirmed after radical hysterectomy. The difference between our case and other LELC cases is that our case showed endocervical mass which is found by hysteroscopy. We had a chance for pathologic diagnosis before the operation.

EBV is thought to be an oncogenic factor in lymphoepithelioma carcinoma of the nasopharynx. This knowledge is more relevant to Asian patients than to those of other ethnicities \[[@B3]\]. However, the clinical pathogenesis of LELC in the cervix remains controversial. Some reports suggest that EBV is an etiologic factor in LELC of the uterine cervix. One report on Taiwanese women with cervical LELC found that EBV was present, as identified by polymerase chain reaction for EBV DNA, in 73.3% (11/15) of 15 LELC patients \[[@B3]\]. However, Chao et al. \[[@B1]\] reported that, of 9 Taiwanese women with uterine cervical LELC, none had EBV, as assayed by *in situ* hybridization for EBV-encoded early RNAs. It has been suggested that EBV does not act as a carcinogenic factor in cervical LELC, but the EBV DNA sequence may be found in lymphocytes that have infiltrated the stroma. In Western women, EBV has never been confirmed to be a factor in cervical LELC \[[@B6][@B7][@B8][@B9]\]. These findings imply that race and geographic factors may influence the role of the EBV gene as an oncogenic factor in uterine cervical LELC \[[@B3]\].

Some reports have demonstrated the influence of HPV as causative agent in cervical LELC in Western women. However, pathogenesis related to the interaction between the virus and epithelioid cells is unclear and controversial \[[@B6][@B8][@B10]\]. The prognosis of cervical LELC is favorable. After surgery, the result of therapeutic response is good.

In conclusion, LELC is rare and difficult to diagnose. Therefore, large-scale research is difficult to conduct. A multicenter, national registration system could be essential for future research about the prognosis and treatment of such a rare disease.
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![(A) Sagittal T2-weighted magnetic resonance imaging scan revealing a well-defined high signal intensity mass, 3.1 cm in size, at the anterior aspect of the endocervix, along with multiple uterine myomas less than 9 cm in size. (B) Macroscopically, the cervix was open at 12 o\'clock. (C) The cells had large, ill-defined cytoplasmic borders, abundant cytoplasm, prominent nucleoli, and syncytial growth patterns (H&E, ×200). (D) Formalin fixed paraffin-embedded tissue used for *in situ* hybridization for Epstein-Barr virus--encoded early RNAs. The result was negative.](ogs-60-118-g001){#F1}

###### Literature review of lymphoepithelioma-like carcinoma of cervix
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  Author                          Country       Article type       No. of case   Age (yr) (or median)   EBV                     HPV                          FIGO stage   Treatment                             Adjuvant treatment       Follow-up (mo) (median)   Follow-up status
  ------------------------------- ------------- ------------------ ------------- ---------------------- ----------------------- ---------------------------- ------------ ------------------------------------- ------------------------ ------------------------- ------------------
  Chao et al. \[[@B1]\]           Taiwan        Original article   9             54 (40--67)            Negative                16(3), 18,31,35, 58, 16/58   IB           RH, BPLND                             Radiotherapy             Mean 112 ( 63--134 )      No recur
  Tseng et al. \[[@B3]\]          Taiwan        Original article   15            56 (37--72)            Positive (73%, 11/15)   16 (20%, 3/15)               IB (9/15)    RH, BPLND (10/15)                                              Mean 45 ( 20--63 )        No recur
                                                                                                                                                             IIA (2/15)   Radiotherapy (5/15)                                                                      
                                                                                                                                                             IIB (4/15)                                                                                            
  Hasumi et al. \[[@B5]\]         Japan         Original article   39            43.5 (30--61)          Not done                Not done                     IB           RH                                                             Mean 58.5 ( 3--60 )       No recur
  Takai et al. \[[@B2]\]          Japan         Case               3             41                     Negative                Negative                     IB1          RH, BPLND                             No report                100                       No recur
                                                                                 69                     Negative                Negative                     IIA          RH, BPLND                             No report                75                        No recur
                                                                                 44                     Negative                Negative                     IB1          RH, BPLND                             No report                15                        No recur
  Saroha et al. \[[@B4]\]         India         Case               2             40                     Not done                Not done                     IB1          RH, BPLND, PALND                      No report                14                        No recur
                                                                                 43                     Not done                Not done                     IB1          RH, BSO, BPLND, PALND                 No report                12                        No recur
  Bais et al. \[[@B6]\]           Netherlands   Case               1             44                     Negative                16, 45                       IB1          RH, BPLND                             None                     No report                 No recur
  Martorell et al. \[[@B7]\]      Spain         Case               4             74                     Negative                Negative                     IB1          Cervicectomy                          No report                84                        No recur
                                                                                 58                     Negative                Negative                     IB1          RH, BPLND                             No report                60                        No recur
                                                                                 77                     Negative                Negative                     II           RH, BPLND                             No report                24                        No recur
                                                                                 67                     Negative                Negative                     IB1          RH, BPLND                             No report                24                        Recur
  Noel et al. \[[@B8]\]           Belgium       Case               2             56                     Negative                16                           IB1          RH, BPLND                             No report                No report                 No recur
                                                                                 53                     Negative                18                           IB1          RH, BPLND                             No report                24                        No recur
  Lopez-Rios et al. \[[@B9]\]     Spain         Case               1             44                     Positive                Not done                     IB1          RH, BPLND                             No report                12                        No recur
  Saylam et al. \[[@B10]\]        Belgium       Case               1             72                     Not done                18                           IB1          RH, BPLND                             None                     No report                 No recur
  Takebayashi et al. \[[@B11]\]   Japan         Case               1             45                     Negative                Not done                     IB2          RH                                    Radiotherapy             4                         No recur
  Kaul et al. \[[@B12]\]          India         Case               1             42                     Not done                Not done                     IB1          RH, BPLND                             No report                12                        No recur
  Kim et al. \[[@B13]\]           Korean        Case               1             57                     Negative                Negative                     IB1          RH, BSO, BPLND, PALND, appendectomy   Paclitaxel + cisplatin   26                        No recur
  Ki et al. \[[@B14]\]            Korean        Case               1             63                     Positive                16                           IB1          RH, BSO, BPLND, appendectomy          None                     34                        No recur
  Yoo et al. \[[@B15]\]           Korean        Case               1             55                     Not done                Not done                     IB1          RH, BSO, BPLND                        None                     12                        No recur

EBV, Epstein-Barr virus; HPV, human papilloma virus; FIGO, International Federation of Gynecology and Obstetrics; RH, radical hysterectomy; BPLND, bilateral pelvic lymph node dissection; PALND, para-aortic lymph node dissection; BSO, bilateral salpingo-oophorectomy; TAH, total abdominal hysterectomy.
